The resulting increased expression of MDM2 can degrade wild-type p53 protein or inhibit wild-type p53 transcriptional activation by proteolysis, providing negative feedback and regulation of wild-type p53 expression, then promotes tumor growth [17]. The gene discussed is TP53; the disease is neoplasm.